NMI-900

**NMI-900** (GSK1070916) is a potent, reversible, ATP-competitive small molecule inhibitor of Aurora B and C kinases with high affinity for Aurora B and a slow dissociation rate, demonstrating anti-proliferative activity in multiple cancer cell lines while sparing non-proliferating normal cells. Developed initially by GSK in partnership with Cancer Research UK's Centre for Drug Development and later licensed exclusively to Nemucore Medical Innovations in 2015, it showed clinical responses in 61% of heavily pretreated patients with advanced solid tumors in a completed Phase 1/2a trial, with neutropenia as the main tolerable adverse event. Nemucore planned Phase 2b trials in platinum-resistant ovarian cancer (mid-2016) and later pivoted to prioritize acute myeloid leukemia (AML) using a proprietary RNA-based companion diagnostic from Medical Prognosis Institute (now Allarity Therapeutics) to select sensitive patients, with Phase 1b/2 trials prepared at Memorial Sloan Kettering and Moffitt Cancer Centers.[1][3][8][9][11][12]

Other names

NMI 900NMI900NMI-900